Patent · US Active

Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds

US11311624B2 · kind B2 · utility

0Cited by

3References

3Claims

0Family size

Assignee

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

Brian D. Ross · Rockford, US
Marcian Van Dort · Ann Arbor, US

Key dates

Filing date	Aug 8, 2018
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Aug 8, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Inhibitors of mTOR, MEK, JAK and PI3K and compositions containing the same are disclosed. Methods of using the inhibitors in the treatment of a variety of diseases and conditions wherein inhibition of one or more of mTOR, MEK, JAK and PI3K provides a benefit also are disclosed. Methods of using chemical attachment moieties and linkers for the purposes of modifying compound solubility and/or lymphatic absorption are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.